Atea Pharmaceuticals, Inc. AVIR

Company Overview

Atea Pharmaceuticals, Inc. is a U.S.-based clinical-stage biopharmaceutical company focused on developing antiviral therapeutics for serious viral diseases. The company operates within the biotechnology and pharmaceutical industries, with an emphasis on oral antiviral medicines targeting RNA viruses. Atea’s primary revenue drivers historically have consisted of collaboration and licensing agreements, while its long-term strategy centers on advancing proprietary drug candidates through clinical development and potential commercialization. The company’s research efforts have primarily focused on hepatitis C virus (HCV) and coronavirus-related therapies, including combination regimens designed to improve treatment outcomes and simplify dosing.

Founded in 2012, Atea was established to leverage nucleoside chemistry and antiviral drug development expertise. The company became publicly traded on Nasdaq under the ticker AVIR in 2020. Atea gained broader market attention through its collaboration with Roche to develop the oral COVID-19 antiviral candidate AT-527, although later-stage study outcomes reduced the strategic emphasis on that program. In recent years, the company has increasingly concentrated resources on hepatitis C programs, particularly nucleotide analog therapies intended to support shorter-duration and more convenient treatment regimens.